International journal of radiation oncology, biology, physics
-
Int. J. Radiat. Oncol. Biol. Phys. · Dec 2007
Restricted field IMRT dramatically enhances IMRT planning for mesothelioma.
To improve the target coverage and normal tissue sparing of intensity-modulated radiotherapy (IMRT) for mesothelioma after extrapleural pneumonectomy. ⋯ Restricted field IMRT provides an improved method to deliver IMRT to a complex target after extrapleural pneumonectomy. An upcoming Phase I trial will provide validation of these results.
-
Int. J. Radiat. Oncol. Biol. Phys. · Dec 2007
Randomized Controlled TrialA phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy.
The quality of life (QOL) and neurocognitive function of patients with brain tumors are negatively affected by the symptoms of their disease and brain radiation therapy (RT). We assessed the effect of prophylactic d-threo-methylphenidate HCl (d-MPH), a central nervous system (CNS) stimulant on QOL and cognitive function in patients undergoing RT. ⋯ Prophylactic use of d-MPH in brain tumor patients undergoing RT did not result in an improvement in QOL.
-
Int. J. Radiat. Oncol. Biol. Phys. · Dec 2007
Multicenter StudyCustomized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes.
To investigate the biochemical control rate in patients undergoing permanent prostate brachytherapy as a function of the biologically effective dose (BED) and risk group. ⋯ These data suggest that permanent brachytherapy dose prescriptions can be customized to risk status. In low-risk patients, achieving a BED of >or=140 Gy might be adequate for prostate-specific antigen control. However, high-risk disease might require a BED dose of >or=200 Gy.